Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
7.6 EUR | 0.00% |
|
-0.65% | -29.63% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company returns high margins, thereby supporting business profitability.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.63% | 341M | - | ||
+25.83% | 47.96B | B- | ||
+46.06% | 41.47B | A | ||
+0.69% | 42.45B | B | ||
+30.52% | 31.6B | B | ||
+22.30% | 28.63B | B- | ||
-6.35% | 28.03B | C | ||
+49.25% | 14.56B | B+ | ||
+49.18% | 14.14B | C+ | ||
+3.45% | 12.58B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2395 Stock
- YB3 Stock
- Ratings Shin Nippon Biomedical Laboratories, Ltd.